comparemela.com
Home
Live Updates
Combo Therapy Prolongs Survival in Gastric Cancer Patients : comparemela.com
Combo Therapy Prolongs Survival in Gastric Cancer Patients
The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.
Related Keywords
United States ,
China ,
Peking ,
Beijing ,
Chinese ,
American ,
Jiafu Ji ,
American Association For Cancer Research ,
Drug Administration ,
Institute For Cancer Research ,
University Cancer Hospital ,
American Association ,
Cancer Research ,
Peking University Cancer Hospital ,
Beijing Institute ,
New Treatment Paradigm ,
Advanced Gastric ,
Noncolorectal Gastrointestinal Cancer ,
Oncolorectal Gi Cancer ,
Chemotherapy ,
Combination Chemotherapy ,
Gastric Cancer ,
Alignant Stomach Neoplasm ,
Stomach Cancer ,
Gastric Carcinoma ,
Toxicology ,
Toxicity ,
Poisoning ,
Toxins ,
Cancer ,
Alignant Neoplasia ,
Arcinoma ,
Alignant Neoplasm ,
Biologic Therapy ,
Iologics ,
Antineoplastic Drug ,
Nti Cancer Agents ,
Rlotinib ,
Efitinib ,
Matinib ,
Ituximab ,
U11248 ,
comparemela.com © 2020. All Rights Reserved.